Amperos Health | $4,200,000 | (Jun 5, 2025)
Manex AI | $9,142,230 | (Jun 5, 2025)
fabriq | $25,000,000 | (Jun 5, 2025)
Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
Obvio | $22,000,000 | (Jun 5, 2025)
Portless | $18,000,000 | (Jun 5, 2025)
Vivrelle | $62,000,000 | (Jun 5, 2025)
Sema4.ai | $25,000,000 | (Jun 5, 2025)
Delpha | $2,000,000 | (Jun 5, 2025)
Compyl | $12,000,000 | (Jun 4, 2025)
Ciroos | $21,000,000 | (Jun 4, 2025)
Clara(US) | $3,100,000 | (Jun 4, 2025)
myLaurel® | $12,000,000 | (Jun 4, 2025)